> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# STERIS Lifts Fiscal 2027 Earnings Outlook To $11.35-$11.55 A Share As Life Sciences Revenue Jumps 18%
- URL: https://www.bullished.co/steris-lifts-fiscal-2027-earnings-outlook-to-11-35-11-55-a-share-as-life-sciences-revenue-ab75b671/
- Published: 2026-11-04T21:53:45.000Z
- Updated: 2026-11-04T21:53:45.000Z
- Description: The sterilization company's new range includes about $0.18 a share from tariff refunds, while one segment's growth outlook was trimmed.
- Author: Matteo Parrino
- Tags: Earnings, STE, Industry: Healthcare

[STERIS](https://www.bullished.co/tag/ste/) now expects adjusted earnings of [$11.35 to $11.55 per diluted share](https://www.sec.gov/Archives/edgar/data/0001757898/000162828026070220/ste9302026ex991.htm?ref=bullished.co) for fiscal 2027, up from $11.10 to $11.30 before, after Life Sciences revenue rose 18% in the second quarter. The company said the new range includes about $0.18 from tariff refunds received year to date.

## A strong quarter, with a tariff assist

STERIS, which sells infection-prevention products and services to healthcare providers and to device and drug manufacturers, reported second-quarter adjusted earnings of [$2.94 per diluted](https://www.globenewswire.com/news-release/2026/11/04/3395890/0/en/steris-announces-financial-results-for-fiscal-2027-second-quarter.html?ref=bullished.co) share, against $2.47 a year earlier. As-reported net income was $213.7 million, or $2.19 per share, versus $191.9 million, or $1.94.

Revenue rose 9% [to $1.6 billion](https://www.globenewswire.com/news-release/2026/11/04/3395890/0/en/steris-announces-financial-results-for-fiscal-2027-second-quarter.html?ref=bullished.co), and constant-currency organic growth was 8%. The pre-tax benefit of tariff refunds on as-reported results was about $20 million, while gross tariff costs stayed flat at $15 million.

CEO Dan Carestio said the updated outlook reflects "stable underlying performance, plus the benefit of tariff refunds received year-to-date." Consolidated revenue growth guidance is unchanged at 7-8% as reported and 6-7% on a constant-currency organic basis.

## Life Sciences leads, sterilization slips

Life Sciences revenue climbed 18% to $170.6 million, helped by 53% growth in capital equipment. Operating income rose to $75.8 million from $59.9 million. The segment's full-year organic growth outlook moves to 9-10% from 6-7%.

Healthcare, the largest segment, grew revenue 9% to $1.1 billion, with operating income of $269.2 million against $259.5 million. Its 6-7% organic outlook is unchanged.

Applied Sterilization Technologies, which serves device and drug makers, saw revenue rise 5% to $295.6 million as capital equipment revenue fell 21%. Its organic growth outlook was trimmed to 6-7% from 7-8%.

## A second restructuring plan

The company approved a second targeted restructuring plan, mainly in Healthcare, covering facility realignment, product rationalization and some organizational changes. Total charges are about $45 million, including about $10 million in cash, and annualized savings are expected at about $9 million.

Cash from operations for the first six months was $656.1 million, down from $707.8 million, which the company attributed mainly to a smaller working-capital contribution. Free cash flow was $492.5 million versus $527.7 million.

Management hosts its earnings call Thursday at 9:00 a.m. ET, and STERIS will issue a revised outlook that includes the proposed Xodus Medical acquisition after that deal closes.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — STERIS plc (STE)](https://www.sec.gov/Archives/edgar/data/0001757898/000162828026070220/ste-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ste9302026ex991.htm — STERIS plc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001757898/000162828026070220/ste9302026ex991.htm?ref=bullished.co) — SEC EDGAR
- [STERIS Announces Financial Results for Fiscal 2027 Second](https://www.globenewswire.com/news-release/2026/11/04/3395890/0/en/steris-announces-financial-results-for-fiscal-2027-second-quarter.html?ref=bullished.co) — globenewswire.com

### More on STERIS

- [STERIS Agrees To Buy Xodus Medical For $2.1 Billion In Cash, With Up To $150 Million Earnout](https://www.bullished.co/steris-agrees-to-buy-xodus-medical-for-2-1-billion-in-cash-with-up-to-150-million-earnout-8c211591/)

[All STERIS (STE) coverage →](https://www.bullished.co/tag/ste/)